



NSX/Media Announcement

IQnovate Expands Executive Team and Scales Up After Strong Listing

22nd February 2012

The world's first contract medical company, IQnovate Limited (IQN), announced today it had appointed a senior medical executive as Business Development Manager. The company has also prepared for growth by leasing larger office space in Sydney's CBD for its headquarters.

"Since successfully completing our initial public offering in December, we have been working hard to scale up our activities," IQN's Executive Chairman and CEO, Mr George Syrmalis, said. "In particular, the hiring of Janine Horton as Business Development Manager will be critical in securing for us contracts with biopharmaceutical, medical equipment and government clients." Mr Syrmalis is world-experienced Australian biopharma industry executive.

Ms Horton was previously employed as a Business Manager at the privately owned research and development company, Regional Health Care Group Ltd. She also has clinical research experience as a former Global Market Development Manager with Nanosonics, a medical technology developer, and worked for St Vincent's Hospital and St John of God.

IQN's unique business model aims to cut its clients' expenses by decreasing overheads and boosting revenue by speeding up the time it takes to register and market their products. Since listing its 20c shares on the National Stock Exchange, strong support from investors has boosted the share price to \$1.40.

About IQnovate:

IQnovate Limited is a contract medical affairs organisation and scientific service provider to the biopharmaceutical industry. The company also extends a premium advisory service to institutional capital investors on biotech investment strategy. Its clients are pharmaceutical, biotechnology, medical device, financial institutions and academic and government organisations. IQnovate focuses on every segment of the drug life cycle, from preclinical-clinical, product pre-launches, right through to RRC (registration, reimbursement and commercialisation) bridging science with business.

For further information:

George Syrmalis, Chairman and Chief Executive Officer +612 8839 5900

Alan Deans, Partner, Last Word Corporate Communications +61427 490 992

Mark Furness, Partner, Last Word Corporate Communications +61419 275 504